NUVB7:30 AMNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Updatenuvationbio.com
NUVB8:00 AMNuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual CongressesPresentation / Abstractnuvationbio.com
NUVB4:05 PMNuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026nuvationbio.com
NUVB8:00 AMNuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Gliomanuvationbio.com
NUVB5:09 PMNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offeringnuvationbio.com
NUVB8:00 AMNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdomnuvationbio.com
NUVB11:58 PMNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notesnuvationbio.com
NUVB8:00 AMNuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meetingnuvationbio.com